User login
Key clinical point: There is no improvement in survival of patients with nonmetastatic gastric adenocarcinoma in selected European countries. The survival has slightly improved in the US and worsened in Sweden.
Major finding: The overall survival (OS) trend improved in the US (hazard ratio [HR] per year 0.99) and worsened in Sweden (HR per year 1.03). There was no improvement in OS trend in the Netherlands, Belgium, Norway, and Slovenia. After adjusting for resection, the OS trend became insignificant in Sweden and improved in the US, Slovenia, and Norway.
Study details: A real-world observational study of individual-level data of 66,398 patients diagnosed with nonmetastatic gastric adenocarcinoma during 2003-2016 in the US and 5 European countries.
Disclosures: This study was supported by Deutsche Krebshilfe. The authors declared no competing interests.
Source: Huang L et al. Survival trends of patients with non-metastatic gastric adenocarcinoma in the US and European countries: The impact of decreasing resection rates. Cancer Commun (Lond). 2022 (Jun 6). Doi: 10.1002/cac2.12318
Key clinical point: There is no improvement in survival of patients with nonmetastatic gastric adenocarcinoma in selected European countries. The survival has slightly improved in the US and worsened in Sweden.
Major finding: The overall survival (OS) trend improved in the US (hazard ratio [HR] per year 0.99) and worsened in Sweden (HR per year 1.03). There was no improvement in OS trend in the Netherlands, Belgium, Norway, and Slovenia. After adjusting for resection, the OS trend became insignificant in Sweden and improved in the US, Slovenia, and Norway.
Study details: A real-world observational study of individual-level data of 66,398 patients diagnosed with nonmetastatic gastric adenocarcinoma during 2003-2016 in the US and 5 European countries.
Disclosures: This study was supported by Deutsche Krebshilfe. The authors declared no competing interests.
Source: Huang L et al. Survival trends of patients with non-metastatic gastric adenocarcinoma in the US and European countries: The impact of decreasing resection rates. Cancer Commun (Lond). 2022 (Jun 6). Doi: 10.1002/cac2.12318
Key clinical point: There is no improvement in survival of patients with nonmetastatic gastric adenocarcinoma in selected European countries. The survival has slightly improved in the US and worsened in Sweden.
Major finding: The overall survival (OS) trend improved in the US (hazard ratio [HR] per year 0.99) and worsened in Sweden (HR per year 1.03). There was no improvement in OS trend in the Netherlands, Belgium, Norway, and Slovenia. After adjusting for resection, the OS trend became insignificant in Sweden and improved in the US, Slovenia, and Norway.
Study details: A real-world observational study of individual-level data of 66,398 patients diagnosed with nonmetastatic gastric adenocarcinoma during 2003-2016 in the US and 5 European countries.
Disclosures: This study was supported by Deutsche Krebshilfe. The authors declared no competing interests.
Source: Huang L et al. Survival trends of patients with non-metastatic gastric adenocarcinoma in the US and European countries: The impact of decreasing resection rates. Cancer Commun (Lond). 2022 (Jun 6). Doi: 10.1002/cac2.12318